OBJECTIVES: This study investigated cognitive impairment in late-life depression in a follow-up design. The main objective was to assess the most important cognitive domains implicated in late-life depression, in patients who underwent pharmacological treatment, in the acute phase and twelve months after. METHODS: Neuropsychological and clinical data were used from the baseline of patients and controls, to determine the cognitive impairment in the acute phase. Patients repeated the neuropsychological assessment at twelve months. RESULTS: There were significant differences between patients and controls at baseline. But in the patients there was no change over twelve months. There were no differences between remitted and non-remitted patients on neuropsychological scores. CONCLUSIONS: The cognitive impairment seen in the elderly depressed patients seems to be a trait characteristic of this mental disease, even when the depressive episode has remitted. Copyright 2003 John Wiley & Sons, Ltd.
OBJECTIVES: This study investigated cognitive impairment in late-life depression in a follow-up design. The main objective was to assess the most important cognitive domains implicated in late-life depression, in patients who underwent pharmacological treatment, in the acute phase and twelve months after. METHODS: Neuropsychological and clinical data were used from the baseline of patients and controls, to determine the cognitive impairment in the acute phase. Patients repeated the neuropsychological assessment at twelve months. RESULTS: There were significant differences between patients and controls at baseline. But in the patients there was no change over twelve months. There were no differences between remitted and non-remitted patients on neuropsychological scores. CONCLUSIONS: The cognitive impairment seen in the elderly depressedpatients seems to be a trait characteristic of this mental disease, even when the depressive episode has remitted. Copyright 2003 John Wiley & Sons, Ltd.
Authors: Michelle E Culang-Reinlieb; Joel R Sneed; John G Keilp; Steven P Roose Journal: Int J Geriatr Psychiatry Date: 2011-09-15 Impact factor: 3.485
Authors: Amy T Peters; Rachel H Jacobs; Natania A Crane; Kelly A Ryan; Sara L Weisenbach; Olusola Ajilore; Melissa Lamar; Michelle T Kassel; Laura B Gabriel; Amy E West; Jon-Kar Zubieta; Scott A Langenecker Journal: Early Interv Psychiatry Date: 2015-07-14 Impact factor: 2.732
Authors: Dora Kanellopoulos; Paul Rosenberg; Lisa D Ravdin; Dalynah Maldonado; Nimra Jamil; Crystal Quinn; Dimitris N Kiosses Journal: Int Psychogeriatr Date: 2020-01-08 Impact factor: 3.878
Authors: Vishal Bali; Michael L Johnson; Hua Chen; Marc L Fleming; Holly M Holmes; Rajender R Aparasu Journal: Ann Pharmacother Date: 2015-11-25 Impact factor: 3.154
Authors: Guy G Potter; H Ryan Wagner; James R Burke; Brenda L Plassman; Kathleen A Welsh-Bohmer; David C Steffens Journal: Am J Geriatr Psychiatry Date: 2013-03 Impact factor: 4.105
Authors: Michelle E Culang; Joel R Sneed; John G Keilp; Bret R Rutherford; Gregory H Pelton; D P Devanand; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2009-10 Impact factor: 4.105